508 patients with untreated metastatic colorectal cancer were randomly assigned to receive either FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin and irinotecan) plus bevacizumab or FOLFIRI (fluorouracil, leucovorin and irinotecan) and bevacizumab (control group). Patients who received FOLFOXIRI and bevacizumab had improved progression-free survival compared with control patients (12.1 versus 9.7 months, P = 0.003), but also had an increased incidence of certain adverse events.
References
Loupakis, F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371, 1609–1618 (2014)
Rights and permissions
About this article
Cite this article
New treatment combination for metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol 11, 702 (2014). https://doi.org/10.1038/nrgastro.2014.190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.190
